开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

已收盘 07-23 15:58:54

1.710

+0.000

0.00%

最高1.730	最低1.690	成交量13.00万
今开1.710	昨收1.710	日振幅2.34%
总市值8.53亿	流通市值8.53亿	总股本4.99亿
成交额22.24万	换手率0.03%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.71,"timestamp":1784793534328,"preClose":1.71,"halted":0,"volume":130000,"delay":0,"changeRate":0,"floatShares":499000000,"shares":499000000,"eps":-0.5152705461631354,"marketStatus":"已收盘","change":0,"latestTime":"07-23 15:58:54","open":1.71,"high":1.73,"low":1.69,"amount":222415,"amplitude":0.023392,"askPrice":1.73,"askSize":5000,"bidPrice":1.71,"bidSize":1500,"shortable":0,"etf":0,"ttmEps":-0.5142212568417421,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784856600000},"marketStatusCode":5,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.71,"openAndCloseTimeList":[[1784770200000,1784779200000],[1784782800000,1784793600000]],"volumeRatio":0.233184,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2653746090","title":"迪哲医药(688192.SH)发预亏，预计半年度归母净亏损2.1亿元左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2653746090","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653746090?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:20","pubTimestamp":1784802006,"startTime":"0","endTime":"0","summary":"预计2026年半年度归属于母公司所有者的扣除非经常性损益后的净亏损2.31亿元左右，同比亏损减少44.90%左右。公司2026年半年度营业收入大幅增长，同时产品研发进展较为顺利，研发投入仍保持较高水平，预计2026年半年度将继续出现归属于母公司所有者的净利润为负的情况，但公司主营业务、核心竞争力没有发生重大不利变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","BK1161","688192","BK0239","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653746675","title":"迪哲医药：预计2026年1-6月扣非后净利润亏损约2.31亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653746675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653746675?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:06","pubTimestamp":1784801168,"startTime":"0","endTime":"0","summary":"证券之星消息，迪哲医药发布业绩预告，预计2026年1-6月扣非后净利润亏损约2.31亿元。迪哲医药2026年一季报显示，一季度公司主营收入2.53亿元，同比上升58.18%；归母净利润-9555.74万元，同比上升50.36%；扣非净利润-1.09亿元，同比上升50.41%；负债率59.01%，财务费用712.85万元，毛利率95.92%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300037337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653474884","title":"7月23日纳微科技涨5.66%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653474884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653474884?lang=zh_cn&edition=full","pubTime":"2026-07-23 16:47","pubTimestamp":1784796441,"startTime":"0","endTime":"0","summary":"证券之星消息，7月23日纳微科技涨5.66%，收盘报36.4元，换手率3.37%，成交量13.59万手，成交额4.93亿元。重仓纳微科技的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共9家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300033284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0229","LU2488822045.USD","159938","09939","BK1515","688690","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653174327","title":"柳药集团：公司现阶段主营业务以医药批发、医药零售和医药工业为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2653174327","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653174327?lang=zh_cn&edition=full","pubTime":"2026-07-23 16:03","pubTimestamp":1784793802,"startTime":"0","endTime":"0","summary":"证券之星消息，柳药集团(603368)07月23日在投资者关系平台上答复投资者关心的问题。投资者提问：公司目前主营疲软，建议利用广西丰富的资源养食蟹猴，需求很大，涨价很猛。柳药集团回复：感谢您对公司的关注！公司现阶段主营业务以医药批发、医药零售和医药工业为主。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300029797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0070","09939","BK0250","BK1515","BK1574","603368","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653713164","title":"楚天科技：长期规划中包含医药装备、医疗设备、食品设备等相关领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2653713164","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653713164?lang=zh_cn&edition=full","pubTime":"2026-07-23 11:44","pubTimestamp":1784778278,"startTime":"0","endTime":"0","summary":"证券之星消息，楚天科技(300358)07月23日在投资者关系平台上答复投资者关心的问题。投资者提问：公司有没有向医疗设备领域探索发展的步伐？比如食品机械设备的也行啊，一个利乐占据了多少市场楚天科技回复：您好！公司长期规划中包含医药装备、医疗设备、食品设备等相关领域，但目前专注于医药装备领域。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300020070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","159873","BK1161","BK0028","BK0077","BK0061","159938","BK1574","09939","BK1515","300358"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653718648","title":"新股消息 | 迪哲医药(688192.SH)港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2653718648","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653718648?lang=zh_cn&edition=full","pubTime":"2026-07-23 10:44","pubTimestamp":1784774673,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，迪哲(江苏)医药股份有限公司(简称：迪哲医药(688192.SH))于2026年1月23日所递交的港股招股书满6个月，于2026年7月23日失效，递表时高盛和华泰国际为其联席保荐人。据招股书，迪哲医药是一家处于商业化阶段的生物制药公司，公司的核心治疗领域是肿瘤及血液系统疾病。公司的上市产品舒沃哲®是全球范围内唯一获批用于治疗EGFR 20号外显子插入突变型肺癌的小分子表皮生长因子受体酪氨酸激酶抑制剂。于2023年度、2024年度、2025年截至9月30日止九个月，该公司实现收入分别为9128.9万元、3.6亿元、5.86亿元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","VXUS","REDS","KCAI","159938","BK0239","BK4127","09939","BK1515","FRHC","BK4585","KCE","BK4588","688192","BK1574","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653791754","title":"信达生物全球首款口服周制剂小分子GLP-1申报临床；药康生物2026年上半年净利润预增46.67%至60.78%｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2653791754","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653791754?lang=zh_cn&edition=full","pubTime":"2026-07-23 07:02","pubTimestamp":1784761351,"startTime":"0","endTime":"0","summary":"｜2026年7月23日星期四｜NO.1信达生物：全球首款口服周制剂小分子GLP-1申报临床7月21日，信达生物IBI3042的临床试验申请获国家药监局受理。今年6月，公司已在美国糖尿病学会（ADA）年会上披露了包括IBI3042在内的多项代谢管线数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233817817194.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233817817194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["JDOC","688046","01801","GLP","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653076922","title":"【新股IPO】上海生生医药向港交所主板递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2653076922","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653076922?lang=zh_cn&edition=full","pubTime":"2026-07-22 23:19","pubTimestamp":1784733541,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所7月22日文件，上海生生医药冷链科技股份有限公司向港交所主板递交上市申请，联席保荐人为中金公司、国金证券 。目前，公司温控供应链服务涵盖项目管理、临床包装与贴签、温控包装、物流与仓储服务、药物回收及销毁，以及其他供应链服务。股权层面，截至最后实际可行日期，鞠继兵与肖忠梅夫妇、宁波弗斯生、宁波宴伽、宁波宴嘉及宁波良生合共有权行使公司约42.62%的表决权，为控股股东。","market":"hk","thumbnail":"https://static.szfiu.com/news/20220324/MzRhMTE1MTUwMjgzODI3Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/MzRhMTE1MTUwMjgzODI3Nw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986545","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","BK1515","HEXmain","BK4127","BK1574","159938","BK1161","KCE","FRHC","09939","REDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653698237","title":"同源康医药-B(02410)对四川汇宇制药股份有限公司提起法律程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2653698237","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653698237?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:56","pubTimestamp":1784732193,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B 发布公告，本公司最近已向长兴县人民法院提交一宗案件，对四川汇宇制药股份有限公司(汇宇)提起法律程序，寻求以下司法确认：一份声称与汇宇订立的TY-9591相关合作协议及经销协议并未成立且属无效。本公司亦收到内江市市中区人民法院就汇宇就据称由本公司与汇宇订立的同一合作协议、经销协议及相关文件所发出的案件受理通知书。两宗案件均已立案，惟尚未在法院审理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02410","BK1161","BK1191","159938","09939","BK1515","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653676503","title":"迪哲医药（688192）披露拟与阿斯利康签署舒沃哲®全球许可协议，7月22日股价下跌1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653676503","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653676503?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:14","pubTimestamp":1784729661,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，迪哲医药报收于60.86元，较前一交易日下跌1.49%，最新总市值为283.1亿元。该股当日开盘60.1元，最高65.9元，最低60.1元，成交额达11.57亿元，换手率为3.96%。近日，迪哲医药披露公告，拟与阿斯利康签署《许可协议》，授予其全球范围内独家开发、商业化舒沃哲的权利。阿斯利康为公司关联法人，本次交易构成关联交易，但不构成重大资产重组。该事项已获董事会审议通过，尚需提交股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","688192","BK1574","BK1161","159938","BK0239","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653744752","title":"Wellington Management Group LLP减持劲方医药-B(02595)8400股 每股作价约34.71港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653744752","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653744752?lang=zh_cn&edition=full","pubTime":"2026-07-22 19:18","pubTimestamp":1784719136,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月20日，Wellington Management Group LLP减持劲方医药-B(02595)8400股，每股作价34.7105港元，总金额约为29.16万港元。减持后最新持股数目约为2444.11万股，最新持股比例为6.95%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02595","BK1574","09939","159938","EWH","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653751185","title":"国家医保局：2025年医保基金共拨付2.74万亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653751185","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653751185?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:39","pubTimestamp":1784716750,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","BK1515","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653510057","title":"医保基金清算提速赋能医药机构发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2653510057","media":"国家医保局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653510057?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:00","pubTimestamp":1784714400,"startTime":"0","endTime":"0","summary":"2025年国家医保局启动清算提质增效三年行动计划，积极优化清算流程，大幅缩短清算周期。2026年全国所有统筹地区在5月27日前全面完成2025年度基金清算，其中，有154个统筹地区在3月底前就完成了上年度清算。　　下一步，国家医保局将以数智化为支撑，持续推动医保基金结算清算迈上新台阶，进一步释放改革红利，让改革惠及更多定点医药机构和广大参保群众。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxyy/2026-07-22/doc-iniispmx2003052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK1161","159938","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653753508","title":"7月22日热景生物跌6.33%，富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653753508","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653753508?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:42","pubTimestamp":1784709772,"startTime":"0","endTime":"0","summary":"证券之星消息，7月22日热景生物跌6.33%，收盘报123.22元，换手率6.04%，成交量5.6万手，成交额7.28亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为富国基金的富国医药创新股票A。富国医药创新股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200034138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","688068","BK1574","BK1515","BK1161","BK0239","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653730012","title":"新叶股份(002476.SZ)产品暂未应用于医药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2653730012","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653730012?lang=zh_cn&edition=full","pubTime":"2026-07-22 15:57","pubTimestamp":1784707023,"startTime":"0","endTime":"0","summary":"格隆汇7月22日丨新叶股份(002476.SZ)在互动平台表示，公司主要产品涵盖聚丙烯酰胺、稠油降粘剂、表面活性剂等，相关产品主要应用于油气开发领域的三次采油作业、废水处理等场景，目前公司产品暂未应用于医药领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260722/32314809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK0144","BK1574","BK1515","002476","BK0004","159938","BK0229","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653778219","title":"港股异动 | 同源康医药-B(02410.HK)高开近15% 与齐鲁制药达成战略合作加速TY-9591商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2653778219","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653778219?lang=zh_cn&edition=full","pubTime":"2026-07-22 09:24","pubTimestamp":1784683457,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02410","BK1161","09939","BK1515","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653782539","title":"创胜集团医药-B(06628.HK)转仓市值总计2786.14万港元 占比5.77% 从星展银行转出2602.19万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653782539","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653782539?lang=zh_cn&edition=full","pubTime":"2026-07-22 08:23","pubTimestamp":1784679828,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1515","06628","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653816697","title":"开拓药业-B获KT International Investment Limited增持14.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653816697","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653816697?lang=zh_cn&edition=full","pubTime":"2026-07-22 07:32","pubTimestamp":1784676720,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新数据显示，7月17日，KT International Investment Limited增持开拓药业-B（09939）14.5万股，每股作价1.713港元，总金额约为24.84万港元。增持后最新持股数目约为5550.78万股，最新持股比例为11.13%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-07-22/doc-iniirshn7914822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0541502299.USD","KT","LU0541501648.USD","SG9999004220.SGD","BK1161","09939","BK1515","BK1574","BK4115"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653786510","title":"亚虹医药获得外观设计专利授权：“内窥镜”","url":"https://stock-news.laohu8.com/highlight/detail?id=2653786510","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653786510?lang=zh_cn&edition=full","pubTime":"2026-07-22 05:42","pubTimestamp":1784670123,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示亚虹医药新获得一项外观设计专利授权，专利名为“内窥镜”，专利申请号为CN202530498544.4，授权日为2026年7月7日。今年以来亚虹医药新获得专利授权5个，较去年同期增加了150%。通过天眼查大数据分析，江苏亚虹医药科技股份有限公司共对外投资了4家企业，参与招投标项目6次；财产线索方面有商标信息136条，专利信息61条，著作权信息10条；此外企业还拥有行政许可20个。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200007419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","09939","BK1161","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653207335","title":"股市必读：新发布《天健会计师事务所（特殊普通合伙）关于大参林医药集团股份有限公司2025年年度报告问询函专项说明》","url":"https://stock-news.laohu8.com/highlight/detail?id=2653207335","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653207335?lang=zh_cn&edition=full","pubTime":"2026-07-22 02:20","pubTimestamp":1784658004,"startTime":"0","endTime":"0","summary":"天健会计师事务所关于大参林医药集团股份有限公司2025年年度报告问询函专项说明天健会计师事务所出具专项说明，确认大参林对2025年年报问询函所涉业务经营、商誉减值、货币资金及应付票据、其他往来款等事项的回复具备合理性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200002847.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603233","09939","BK0114","BK0209","BK1515","BK0185","159938","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.0806},{"period":"1month","weight":-0.2434},{"period":"3month","weight":-0.3596},{"period":"6month","weight":-0.3958},{"period":"1year","weight":-0.3105},{"period":"ytd","weight":-0.1276}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0473},{"period":"3month","weight":-0.0395},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.020286},{"month":2,"riseRate":0.666667,"avgChangeRate":0.174983},{"month":3,"riseRate":0.333333,"avgChangeRate":0.058562},{"month":4,"riseRate":0.666667,"avgChangeRate":0.374359},{"month":5,"riseRate":0.5,"avgChangeRate":0.006013},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.081543},{"month":7,"riseRate":0.571429,"avgChangeRate":0.098842},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}